Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Proactive - Interviews for investors

Proactive - Interviews for investors artwork

Custom Health CEO targets profitability by late 2027 after 220% revenue surge

Nov 19, 20265 minAudioEpisode 15121
ShareXLinkedInFacebookWhatsAppEmail

Custom Health Holdings Inc (TSX:CHLT) CEO Shane Bishop talked with Proactive's Stephen Gunnion about the company's third-quarter financial results, which saw revenue jump 220% to $14.4 million, alongside its acquisition strategy, smart medication technology and plans to improve margins and work towards profitability by late 2027. Bishop explained that the significant increase in revenue largely reflected the acquisition of InnovativeRx, which aligns with Custom Health's strategy of acquiring pharmacies in geographical markets where it already has payer relationships supporting in-home technology and clinical services. "We have seen organic growth on top of the baseline revenue that we brought in due to that acquisition," Bishop said, highlighting the company's progress in building revenue beyond its acquired pharmacy operations. The discussion also covered Custom Health's decision to bring Spencer Health Solutions and its smart medication dispensing technology fully in-house. Bishop outlined how controlling device costs, consolidating support functions and owning intellectual property could support future margin expansion. He also emphasised the importance of retaining control over patient data as the company looks to integrate artificial intelligence and demonstrate improved outcomes and returns for payers. Turning to the company's partnership with BKC Pain Specialists, Bishop highlighted encouraging medication adherence results among complex patient populations. He also discussed how patient-reported outcomes are supporting Custom Health's clinical services and SaaS technology revenue alongside its pharmacy business, potentially creating opportunities to engage larger healthcare providers. Looking ahead, Bishop identified continued acquisitions, revenue growth, cost control and access to capital markets as priorities. The company is targeting the back end of 2027 for its profitability ambitions, with execution and margin expansion central to that objective. Visit Proactive's YouTube channel for more interviews and updates on publicly traded companies. Don't forget to like this video, subscribe to the channel and enable notifications to stay informed about future content. Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy #CustomHealth #ShaneBishop #HealthcareTechnology #InnovativeRx #SpencerHealthSolutions #DigitalHealth #MedicationAdherence #PharmacyAcquisitions #HealthcareInnovation #RevenueGrowth #SmartMedicationDispenser #PatientOutcomes #HealthTech #ProactiveInvestors

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Saturna Capital analyst flags global AI opportunities and risks of soaring investment

    Nov 20, 20267 minAudio

    Saturna Capital senior investment analyst and portfolio manager Levi Stewart Zurbrugg talked with Proactive's Stephen Gunnion about global equity opportunities, the international AI supply chain, rising interest rates...

    Credit the people on this episode

  2. Sprott Asset Management's Jacob White on uranium stocks sell-off and the case for a recovery

    Nov 20, 20267 minAudio

    Sprott Asset Management Director of ETF Product Management Jacob White talked with Proactive's Stephen Gunnion about the sharp sell-off in uranium mining stocks, the disconnect with physical uranium prices and the...

    Credit the people on this episode

  3. XanaMIA results: What's next for Actinogen Medical?

    Nov 20, 20266 minAudio

    Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study...

    Credit the people on this episode

  4. Parbo Resources uncovers new greenstone belt at Mount Padbury

    Nov 20, 20266 minAudio

    Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone...

    Credit the people on this episode

  5. Arrow Exploration CEO on Icaco success, record production and next drilling targets

    Nov 19, 20264 minAudio

    Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded...

    Credit the people on this episode